孟鲁司特对支气管扩张症患者IL-17和IL-10表达的影响以及临床疗效分析  

Effect of montelukast on IL-17 and IL-10 expression in patients with bronchiectasis and its clinical efficacy

作　　者：李少琳[1] 方燕芬[1] 刘巧莲[1] 

机构地区：[1]潮州市潮安区庵埠华侨医院药剂科,广东潮州515638

出　　处：《临床肺科杂志》2016年第4期739-742,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察孟鲁司特钠对支气管扩张症患者IL-17和IL-10表达的的影响，并分析了其临床疗效。方法收集2013年2月～2015年1月潮州市潮安区庵埠华侨医院治疗的NCFB患者82例，患者随机分为常规治疗对照组和孟鲁司特钠治疗组，每组41例。ELISA法测定痰液中IL-17、IL-10、IL-6和TNF-α表达水平。比较两组肺功能指标、临床症状评分和急性加重次数。结果治疗后两组IL-17、IL-6和TNF-α表达水平均出现减低和IL-10表达水平均出现升高（P〈0．05和P〈0．01），但治疗组IL-17、IL-6和TNF-α表达水平显著低于对照组（P〈0．05），IL-10表达水平又显著高于对照组（P〈0．05）。治疗后两组FEV1％和FEV1／FVC肺功能指标均出现升高（P〈0．05和P〈0．01），但治疗组FEV1％和FEV1／FVC均显著高于对照组（P〈0．05）。治疗后两组咳嗽程度评分和咳痰量评分均减低（P〈0．05和P〈0．01），但治疗组咳嗽程度评分和咳痰量评分均显著低于对照组（P〈0．05）。治疗组治疗期间急性加重1．82±0．35次，显著低于对照组的2．76±0．54次（P〈0．05）。结论孟鲁司特钠可以调节支气管扩张症患者IL-17和IL-10因子的体内平衡，抑制气道局部高炎症反应，保护患者肺功能损伤，减少急性加重次数，临床疗效显著，具有一定的临床应用价值。Objective To detect the effect of Montelukast on IL-17 and IL-10 expression in patients with bronchiectasis and explore its clinical efficacy. Methods A total of 82 patients were enrolled in this study, and they were randomly divided into the control group （n = 41 ） and the montelukast treatment group （n = 41 ）. The expression of IL-17, IL-10, IL-6, and TNF-α were detected by ELISA analysis. The pulmonary function, clinical symptom score and the number of acute exacerbation of the two groups were compared. Results After treatment, IL-17, IL- 6, and TNF-α decreased and IL-10 increased in the two groups （P 〈0. 05 or P 〈0. 01 ）. However, the improvement was more pronounced in the treatment group than in the control group （P 〈0. 05）. FEV1% and FEV1/FVC was obviously higher in the treatment group than in the control group （P 〈 0. 05）. The cough severity score and sputum score was lower in the treatment group than in the control group （P 〈 0. 05）. During the treatment, the number of acute exacerbation was 1.82 ± 0. 35 times in the treatment group, which was significantly lower than that in the control group （2. 76 ± 0. 54 times） （P 〈 0. 05 ）. Conclusion Montelukast can regulate the balance of IL-17 and IL-10 in patients with bronchiectasis, inhibit airway local inflammatory response, protect pulmonary function, and reduce the number of acute exacerbation.

关 键 词：支气管扩张症 孟鲁司特钠 白介素-17 白介素-10 

分 类 号：R562.22[医药卫生—呼吸系统]